Author: Mohammed Omer Abdelrahman Dahab / Editor: Spyridon Karageorgos / Codes: / Published: 08/06/2026
This module explores respiratory complications related to e-cigarette use, highlighting hypersensitivity pneumonitis (HP) and e-cigarette or vaping-associated lung injury (EVALI). It covers the clinical presentation, epidemiology and diagnostic criteria for these conditions, including recognising symptoms like shortness of breath and cough.
Learning objectives
After completing this session, you will be able to:
- Recognise and manage respiratory complications linked to e-cigarette use, particularly hypersensitivity pneumonitis (HP) and e-cigarette or vaping associated lung injury (EVALI)
- Utilise the Yellow Card Scheme to report any adverse reactions or vaping-related health concerns
References
- Zulfiqar H, Sankari A, Rahman O. Vaping-Associated Pulmonary Injury. [Updated 2023 Jun 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-.
- Medicines and Healthcare products Regulatory Agency (MHRA). E-cigarette use or vaping: reporting suspected adverse reactions, including lung injury. Drug Safety Update, MHRA. Gov.UK. 2020.
- New England Journal of Medicine. ECigarettes and VapingRelated Disease. Special Issue. 2019.
- American Thoracic Society. Ecigarette or Vaping Product UseAssociated Lung Injury (EVALI): Clinician Information.
- Rebuli ME, Rose JJ, Nol A, et al. The Ecigarette or Vaping Product UseAssociated Lung Injury Epidemic: Pathogenesis, Management, and Future Directions. Ann Am Thorac Soc. 2023;20(1):117.
